title: [Interactions between oral anticoagulants and other medication in emergency department--a pharmacoepidemiologic approach].
abstract: Oral anticoagulants (OAC) are commonly used as a life-long therapy in the prevention of systemic embolism in patients with atrial fibrillation, valvular heart disease, prosthetic heart valves, and in the primary and secondary prevention of venous thromboembolism, in patients with acute myocardial infarction and angina pectoris. Drugs, herbs, and multivitamin supplements can alter the absorption, pharmacokinetics or pharmacodynamics of OAC.
  
  
  OBJECTIVE
  To investigate the possible interactions between oral anticoagulants and different drugs administered in patients in emergency department.
  
  
  METHODS
  This 1-year exploratory investigation on 93 patients on OAC (aged 30 - 85 years), admitted at two emergency departments of the Iasi "Sf. Spiridon" Hospital and Piatra Neamţ Hospital, consisted in their medical records analysis: diagnosis, recommended treatement. Data were scored and statistically analyzed by t-test (Windows Excel). The experimental protocol was in agreement with the recommendations of the Gr.T. Popa University Committee for Research and Ethical Issues.
  
  
  CONCLUSIONS
  Analysis and statistical processing of data shows that during the study period 56 patients which received oral anticoagulant therapy associated with different other medication belonged to the 60 and 80 years age group. This finding suggests that the pathology is represented especially by atrial fibrillation and myocardial infarction. The correlation between the therapy consisting in OAC and sartan or nonsteroidal anti-inflammatory drugs and International Normalized Ratio (INR), revealed a high level of anticoagulation and an increase in hemorragic complications.
authors: Universităţii de Medicină şi Farmacie "Gr. T. Popa" Iaşi, România.
authors: F
authors: F
authors: Apostoae
authors: Liliana
authors: L
authors: Tarţău
authors: Cătălina-Elena
authors: CE
authors: Lupuşoru
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D047228:Angiotensin II Type 1 Receptor Blockers / Q000008:administration & dosage / Q000009:adverse effects; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000009:adverse effects; D000925:Anticoagulants / Q000008:administration & dosage* / Q000009:adverse effects; D001281:Atrial Fibrillation / Q000188:drug therapy; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D004636:Emergency Service, Hospital; D005260:Female; D006349:Heart Valve Diseases / Q000188:drug therapy; D006350:Heart Valve Prosthesis / Q000009:adverse effects; D006470:Hemorrhage / Q000139:chemically induced / Q000517:prevention & control; D006801:Humans; D008297:Male; D008875:Middle Aged; D012383:Romania; D020521:Stroke / Q000188:drug therapy / Q000517:prevention & control; D054556:Venous Thromboembolism / Q000209:etiology / Q000517:prevention & control*
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000925:Anticoagulants